How Candel Therapeutics’ 2026 Q3 Results Propel Its Oncolytic Viral Cancer Therapy to FDA Approval
Candel Therapeutics reports $203 M cash, plans 2027 FDA BLA for prostate cancer, shows phase‑2a lung results and strong leadership, boosting investor confidence.
2 minutes to read


